Cure My Disease

Don't miss your cure!

 Log in / Sign up

Double-Drug attack on cholesterol: could two be better than one?

NCT ID NCT07581808

Recruiting now Disease control Sponsor: University Medical Centre Ljubljana Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether combining two different cholesterol-lowering drugs (inclisiran and alirocumab) works better than using either alone. About 60 adults with high heart risk who cannot take statins will be assigned to one of three groups. The goal is to see if the combo lowers 'bad' cholesterol more effectively and safely over 9 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERCHOLESTEROLEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atherosclerosis atherosclerotic cardiovascular disease Hypercholesterolemia hyperlipidemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) HYPERCHOLESTEROLEMIA

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University Medical Centre Ljubljana

    RECRUITING

    Ljubljana, 1000, Slovenia

    Contact

    Contact Email: •••••@•••••

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact